Jinglin Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jinglin Shi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Biao Qian
Department of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China
2 shared publications - Gengqing Wu
Department of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China
2 shared publications - Guancheng Xiao
Department of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China
2 shared publications - Hui Xu
Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
2 shared publications - Junrong Zou
The First Clinical College, Gannan Medical University, Ganzhou, China
2 shared publications - Kaiyang Qiu
Department of Urology, Wan’an People’s Hospital, Ji’an, China
2 shared publications
Latest Publications
- Open Access
- 3 January 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (1) , 1-3
Correction: Knockdown of ubiquitin-like modifier-activating enzyme 2 promotes apoptosis of clear cell renal cell carcinoma cells
- 3 January 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (1) , 1-3
Open AccessCorrection: Knockdown of ubiquitin-like modifier-activating enzyme 2 promotes apoptosis of clear cell renal cell carcinoma cells
- Open Access
- 9 November 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (11) , 1-10
Knockdown of ubiquitin-like modifier-activating enzyme 2 promotes apoptosis of clear cell renal cell carcinoma cells
Small ubiquitin-related modifier (SUMO) proteins are involved in the development of tumors. Ubiquitin-like modifier-activating enzyme 2 (UBA2) is an important member of the SUMO modification system; however, its role in clear cell renal cell carcinoma (ccRCC) is unclear. Therefore, we investigated the expression and function of UBA2 in ccRCC. Both mRNA and protein expression levels of UBA2 were found to be higher in ccRCC than in normal renal tissues and significantly related to the tumor size, Fuhrman grade, and tumor stage. UBA2 knockdown inhibited ccRCC cell growth, promoted apoptosis in vitro and in vivo, and decreased the abundance of a p53 mutant, c-Myc, and key enzymes of the SUMO modification system. Meanwhile, overexpression of UBA2 had the opposite effects. Overexpression of the p53 mutant or c-Myc alleviated the effects of UBA2 knockdown on ccRCC cell proliferation and apoptosis. In conclusion, targeting UBA2 may have a therapeutic potential against ccRCC.
- 9 November 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (11) , 1-10
Open AccessKnockdown of ubiquitin-like modifier-activating enzyme 2 promotes apoptosis of clear cell renal cell carcinoma cells
Small ubiquitin-related modifier (SUMO) proteins are involved in the development of tumors. Ubiquitin-like modifier-activating enzyme 2 (UBA2) is an important member of the SUMO modification system; however, its role in clear cell renal cell carcinoma (ccRCC) is unclear. Therefore, we investigated the expression and function of UBA2 in ccRCC. Both mRNA and protein expression levels of UBA2 were found to be higher in ccRCC than in normal renal tissues and significantly related to the tumor size, Fuhrman grade, and tumor stage. UBA2 knockdown inhibited ccRCC cell growth, promoted apoptosis in vitro and in vivo, and decreased the abundance of a p53 mutant, c-Myc, and key enzymes of the SUMO modification system. Meanwhile, overexpression of UBA2 had the opposite effects. Overexpression of the p53 mutant or c-Myc alleviated the effects of UBA2 knockdown on ccRCC cell proliferation and apoptosis. In conclusion, targeting UBA2 may have a therapeutic potential against ccRCC.